semaglutide patent expiration us Ozempic's problem: how Novo Nordisk lost control of a blockbuster drug. 💉 Demand for GLP-1 weight-loss drugs has exploded, turning Ozempic into a $40bn+ revenue engine for Novo Nordisk. But, despite New Delhi, March 20, 2026

Many UK residents are searching for next-generation obesity treatments due to limited access to GLP-1 medications like Wegovy, ongoing NHS shortages, and strict patient eligibility criteria

Prospective studies are needed to determine the mechanisms behind these findings

- - are the result of over 20 years of research by a team of 30+ metabolic health experts

Both of these medications are GLP-1/GIP receptor agonists, which are commonly grouped with GLP-1 receptor agonists like Ozempic, even though they differ in one key way

Prevalence and Correlates of Coronary Microvascular Dysfunction in Heart Failure with Preserved Ejection Fraction: PROMIS-HFpEF

Fourth, there is no regulatory or employer demand